Background RA is a chronic systemic inflammatory disorder with a prevalence of up to 1%. In the absence of adequate treatment, progressive joint deformity and loss of function occurs with associated premature cardiovascular morbidity. Tocilizumab (TCZ) [1] , a humanized anti IL-6 receptor (anti IL-6R) antibody, has been shown in several large randomized controlled trials to be efficacious and well tolerated in the treatment of RA.
Need for guidelines
A number of systematic literature reviews assessing both the efficacy and safety of TCZ in RA have been published in the last few years, including a Cochrane review in 2010 [2] . The National Institute for Health and Care Excellence (NICE) produced a guideline for the use of TCZ in 2011 [3] , which was reviewed in 2012 [4] . Recently the European League Against Rheumatism published a consensus statement on the use of TCZ across all indications [5, 6] . Despite these, specific guidance on the use of TCZ for RA in the context of routine clinical practice in the UK and a NICE has accredited the process used by the BSR to produce its treatment of psoriatic arthritis with biologics guidance. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation. pragmatic approach to the monitoring and management of its adverse effects were felt to be lacking.
Objective of the guideline
The objectives of the guideline was to provide evidencebased recommendations for the safe and effective use of i.v. TCZ in patients with RA.
Target audience
The guideline is aimed principally at rheumatologists, rheumatology nurses/allied health professionals and rheumatology specialty registrars in the UK. It may also be of use to other secondary care physicians and general practitioners involved in the management of patients with RA.
Areas not covered 
Key recommendations from the guideline

